Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eupraxia Pharmaceuticals ( (TSE:EPRX) ) has provided an update.
Eupraxia Pharmaceuticals, a clinical-stage biotech specializing in locally delivered, extended-release drugs built on its Diffusphere technology platform, is advancing candidates such as EP-104GI for eosinophilic esophagitis and EP-104IAR for knee osteoarthritis pain, with broader ambitions in gastrointestinal, joint and oncology indications. The company, which previously reported that its Phase 2b SPRINGBOARD trial of EP-104IAR met its primary endpoint, continues to build a diversified pipeline of long-acting formulations aimed at improving safety, tolerability and durability for approved and novel therapies.
On April 22, 2026, Eupraxia announced it will present four abstracts at the Digestive Disease Week annual meeting in Chicago from May 2–5, 2026, highlighting clinical data from its ongoing Phase 1b/2 RESOLVE trial of EP-104GI in eosinophilic esophagitis. The presentations will cover dose escalation, durability of histologic, endoscopic and dysphagia improvements, and optimization of dose and injection patterns, while a separate virtual investor event at DDW on May 4, 2026, will showcase key opinion leaders and emphasize EP-104GI’s potential to prevent esophageal strictures, underscoring the program’s strategic importance and visibility with both clinicians and investors.
The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.
Spark’s Take on EPRX Stock
According to Spark, TipRanks’ AI Analyst, EPRX is a Neutral.
The score is held back primarily by the pre-revenue model with widening losses and rising cash burn, despite a notably improved, low-debt balance sheet. Technical indicators also reflect weak near-term momentum, and valuation signals are limited by negative earnings and lack of dividend support.
To see Spark’s full report on EPRX stock, click here.
More about Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on locally delivered, extended-release therapies targeting areas of high unmet medical need, particularly pain and inflammatory gastrointestinal diseases. Its proprietary Diffusphere micro-sphere technology is designed for hyper-local, prolonged drug delivery, and its pipeline includes EP-104GI for eosinophilic esophagitis and EP-104IAR for knee osteoarthritis pain, alongside potential programs in oncology and other inflammatory indications.
Average Trading Volume: 77,825
Technical Sentiment Signal: Buy
Current Market Cap: C$614.5M
Learn more about EPRX stock on TipRanks’ Stock Analysis page.